Logo

Janssen Returns its Exclusive Rights to Develop and Commercialize Hanmi's Antidiabetic Obesity Therapy

Share this

Janssen Returns its Exclusive Rights to Develop and Commercialize Hanmi's Antidiabetic Obesity Therapy

Shots:

  • Janssen has decided to return its rights of Hanmi’s HM12525A due to inability of the therapy to control blood glucose level in obese patient though the drug achieved the 1EPs of weight reduction
  • In Nov’ 2015- Janssen licensed exclusive WW rights (Ex- Korea and China) of HM12525A from Hanmi for $915M. Additionally- with the termination of deal Hanmi will not return the upfront value of $105M to Janssen
  • Hanmi’s HM12525A is a dual GLP-1/Glucagon receptor agonist being developed for weight loss and blood glucose control in patients with diabetes

Click here to read full press release/ article

Ref: Hanmi | Image:Janssen 


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions